Neurogen Arthritis Drug a Failure
Neurogen Corp. said on Tuesday it is unlikely it will continue development of its drug NGD 2000-1 for adult rheumatoid arthritis patients after it failed to meet a clinical trial’s objective.
Neurogen Corp. said on Tuesday it is unlikely it will continue development of its drug NGD 2000-1 for adult rheumatoid arthritis patients after it failed to meet a clinical trial’s objective. The drug did not show an effect regarding a change in C-reactive proteins, a marker of rheumatoid arthritis in patient blood samples, when compared with a placebo, the company said. (Source: Reuters Health, June 2004)
Dates
Tags
Created by: